StockNews.com started coverage on shares of Gilead Sciences ( NASDAQ:GILD – Get Rating ) in a report released on Thursday. The brokerage issued a strong-buy rating on the biopharmaceutical company's stock. Other equities analysts have also recently issued research reports about the stock. Morgan Stanley raised their price target on shares of Gilead Sciences from $81.00 to $85.00 and gave the company an equal weight rating in a research report on Wednesday, April 12th. BMO Capital Markets raised shares of Gilead Sciences from a market perform rating to an outperform rating and boosted their price objective for the stock from $90.

https://www.dailypolitical.com/2023/05/21/gilead-sciences-nasdaqgild-coverage-initiated-by-analysts-at-stocknews-com.html

#dailypolitical